Global Community

MindWalk Holdings Corp. (NASDAQ: HYFT) presents a classic case of market mispricing driven by a transitional lag.Read more

This mining company’s outlook changes fast if gold and silver prices rise and it hits its production and cost targets. See how a ramp-up at its operations, plus debt payoff or new discoveries, could boost cash generation—or how missed guidance could derail it.Read more

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense.Read more

UUE Holdings Bhd may be one of the more undervalued infrastructure-related stocks on Bursa Malaysia today, with its current valuation appearing disconnected from the company's growing earnings potential and healthy order book. The group currently has an outstanding order book exceeding RM500 million , providing strong revenue visibility over the coming years.Read more

The Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.Read more

What Does Mastercard Do? Most people should already be familiar with this company, but for those who aren't: Mastercard runs the rails connecting banks, merchants, and the billions of cards carrying its brand.Read more

KITZ makes a bold move into the heart of the chipmaking supply chain by buying VTEX, turning it into a serious second-choice supplier for equipment makers that want an alternative to the dominant player. The deal is timed when the industry is coming off a lull, so a rebound in chip-factory spending could make this shift look bigger than the market expects.Read more

A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more

Novo Nordisk has gone from a steady insulin business to one of the key players behind the new wave of weight-loss and diabetes medicines, and the market may be overlooking how durable that shift is. Even with near-term pressure from pricing talks and production limits, wider insurance coverage, new product launches, and a deep pipeline could keep demand growing for years.Read more